Detalles de la búsqueda
1.
Changes detected in the genome sequences of Escherichia coli, Listeria monocytogenes, Vibrio parahaemolyticus, and Salmonella enterica after serial subculturing.
Can J Microbiol
; 65(11): 842-850, 2019 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-31356758
2.
A proposed harmonized LPS molecular-subtyping scheme for Cronobacter species.
Food Microbiol
; 50: 38-43, 2015 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-25998813
3.
ABSORB II randomized controlled trial: a clinical evaluation to compare the safety, efficacy, and performance of the Absorb everolimus-eluting bioresorbable vascular scaffold system against the XIENCE everolimus-eluting coronary stent system in the treatment of subjects with ischemic heart disease caused by de novo native coronary artery lesions: rationale and study design.
Am Heart J
; 164(5): 654-63, 2012 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-23137495
4.
Evaluation of the second generation of a bioresorbable everolimus drug-eluting vascular scaffold for treatment of de novo coronary artery stenosis: six-month clinical and imaging outcomes.
Circulation
; 122(22): 2301-12, 2010 Nov 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-21098436
5.
Four-year clinical follow-up of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with de novo coronary artery lesions: the SPIRIT II trial.
Catheter Cardiovasc Interv
; 77(7): 1012-7, 2011 Jun 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-20824770
6.
A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods.
Lancet
; 373(9667): 897-910, 2009 Mar 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-19286089
7.
An everolimus-eluting stent versus a paclitaxel-eluting stent in small vessel coronary artery disease: a pooled analysis from the SPIRIT II and SPIRIT III trials.
Catheter Cardiovasc Interv
; 76(1): 60-6, 2010 Jul 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-20578194
8.
Five-year long-term clinical follow-up of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo coronary artery lesions: the SPIRIT FIRST trial.
Catheter Cardiovasc Interv
; 75(7): 997-1003, 2010 Jun 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-20517959
9.
Efficacy of everolimus eluting stent implantation in patients with calcified coronary culprit lesions: two-year angiographic and three-year clinical results from the SPIRIT II study.
Catheter Cardiovasc Interv
; 76(5): 634-42, 2010 Nov 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-20690152
10.
Systemic exposure of everolimus after stent implantation: a pharmacokinetic study.
Am Heart J
; 156(4): 751.e1-7, 2008 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-18926156
11.
Growth and survival of Enterobacter sakazakii in human breast milk with and without fortifiers as compared to powdered infant formula.
Int J Food Microbiol
; 122(1-2): 171-9, 2008 Feb 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-18207600
12.
Incidence and Potential Mechanism(s) of Post-Procedural Rise of Cardiac Biomarker in Patients With Coronary Artery Narrowing After Implantation of an Everolimus-Eluting Bioresorbable Vascular Scaffold or Everolimus-Eluting Metallic Stent.
JACC Cardiovasc Interv
; 8(8): 1053-1063, 2015 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-26205444
13.
Dynamics of vessel wall changes following the implantation of the absorb everolimus-eluting bioresorbable vascular scaffold: a multi-imaging modality study at 6, 12, 24 and 36 months.
EuroIntervention
; 9(11): 1271-84, 2014 Mar 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-24291783
14.
Five-year long-term clinical follow-up of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with de novo coronary artery disease: the SPIRIT II trial.
EuroIntervention
; 8(9): 1047-51, 2013 Jan 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-23339811
15.
The edge vascular response following implantation of the Absorb everolimus-eluting bioresorbable vascular scaffold and the XIENCE V metallic everolimus-eluting stent. First serial follow-up assessment at six months and two years: insights from the first-in-man ABSORB Cohort B and SPIRIT II trials.
EuroIntervention
; 9(6): 709-20, 2013 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-23628499
16.
Clinical and intravascular imaging outcomes at 1 and 2 years after implantation of absorb everolimus eluting bioresorbable vascular scaffolds in small vessels. Late lumen enlargement: does bioresorption matter with small vessel size? Insight from the ABSORB cohort B trial.
Heart
; 99(2): 98-105, 2013 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-23118346
17.
Four-year clinical follow-up of the ABSORB everolimus-eluting bioresorbable vascular scaffold in patients with de novo coronary artery disease: the ABSORB trial.
EuroIntervention
; 7(9): 1060-1, 2012 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-21959320
18.
First serial assessment at 6 months and 2 years of the second generation of absorb everolimus-eluting bioresorbable vascular scaffold: a multi-imaging modality study.
Circ Cardiovasc Interv
; 5(5): 620-32, 2012 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-23048057
19.
Circumferential evaluation of the neointima by optical coherence tomography after ABSORB bioresorbable vascular scaffold implantation: can the scaffold cap the plaque?
Atherosclerosis
; 221(1): 106-12, 2012 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-22209268
20.
Vascular response of the segments adjacent to the proximal and distal edges of the ABSORB everolimus-eluting bioresorbable vascular scaffold: 6-month and 1-year follow-up assessment: a virtual histology intravascular ultrasound study from the first-in-man ABSORB cohort B trial.
JACC Cardiovasc Interv
; 5(6): 656-65, 2012 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-22721662